<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02536196</url>
  </required_header>
  <id_info>
    <org_study_id>REFLECT</org_study_id>
    <nct_id>NCT02536196</nct_id>
  </id_info>
  <brief_title>The REFLECT Trial: Cerebral Protection to Reduce Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation</brief_title>
  <official_title>A Randomized Evaluation of the TriGuard Embolic Deflection Device to Reduce the Impact of Cerebral Embolic Lesions After Transcatheter Aortic Valve Implantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Keystone Heart</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Keystone Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Keystone Heart TriGuard™ HDH is an aortic embolism deflection device intended to reduce
      the amount of embolic material that may enter the carotid, subclavian, and vertebral arteries
      during transcatheter heart valve implantation.

      The objective of the study is to assess the safety and efficacy of the TriGuard™ HDH embolic
      deflection device in patients undergoing transcatheter aortic valve implantation (TAVI), in
      comparison with an active control group of patients undergoing unprotected TAVI.

      Subjects with indications for TAVI and who meet study eligibility criteria will be randomized
      2:1 to one of two treatment arms: 1) Intervention: Embolic protection device (TriGuard™) with
      transcatheter aortic valve implantation or 2) Control: Unprotected transcatheter aortic valve
      implantation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>30 Days</time_frame>
    <description>Combined safety endpoint at 30 days defined according to VARC-2 (&quot;TAVI early safety&quot;) as a composite of:
All-cause mortality
All stroke (disabling and non-disabling)
Life-threatening or disabled bleeding
Acute kidney injury - Stage 2 or 3 (including renal replacement therapy)
Coronary artery obstruction requiring intervention
Major vascular complication, and
Valve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Efficacy Endpoint</measure>
    <time_frame>Pre-discharge through 30-days</time_frame>
    <description>Hierarchical composite efficacy endpoint, determined by pair-wise comparisons among all subjects according to the following pre-specified hierarchy of adverse outcomes:
All-cause mortality or any stroke (disabling or non-disabling) [evaluated at 30 days]
NIHSS worsening (increase from baseline) or Montreal Cognitive Assessment worsening (decrease from baseline) [evaluated at post-procedure/pre-discharge]
Total volume of cerebral ischemic lesions detected by diffusion-weighted magnetic resonance imaging (DW-MRI) 2 to 5 days post-procedure</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embolic Protection with transcatheter aortic valve implantation (TAVI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Transcatheter aortic valve implantation (TAVI) without embolic protection</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embolic Protection Device</intervention_name>
    <description>Embolic protection</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transcatheter aortic valve implantation (TAVI)</intervention_name>
    <description>Transcatheter aortic valve implantation (TAVI)</description>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Subjects must meet ALL of the following criteria:

        General Inclusion Criteria

          1. The patient is a male or non-pregnant female ≥18 years of age

          2. The patient meets indications for transcatheter aortic valve implantation (TAVI)

          3. The patient is willing to comply with protocol-specified follow-up evaluations

          4. The patient, or legally authorized representative, has been informed of the nature of
             the study, agrees to its provisions and has provided written informed consent,
             approved by the appropriate Institutional Review Board (IRB) or Ethics Committee (EC).

        Potential Subjects will be excluded if ANY of the following criteria apply:

        General Exclusion Criteria

          1. Patients undergoing transcatheter aortic valve implantation (TAVI) via the
             trans-axillary, trans-subclavian, or trans-aortic route

          2. Patients undergoing transcatheter aortic valve implantation (TAVI) via the transapical
             approach due to friable or mobile atherosclerotic plaque in the aortic arch

          3. Patients with a previously implanted prosthetic aortic valve (i.e., planned
             valve-in-valve transcatheter aortic valve implantation (TAVI))

          4. Pregnant or nursing subjects and those who plan pregnancy in the period up to 1 year
             following index procedure. Female subjects of child-bearing potential must have a
             negative pregnancy test done within 14 days prior to index procedure per site standard
             test

          5. Patients with known diagnosis of acute myocardial infarction (AMI) within 72 hours
             preceding the index procedure (according to definition) or AMI &gt;72 hours preceding the
             index procedure, in whom Creatine Kinase (CK) and CK-MB have not returned to within
             normal limits at the time of procedure, or patients who are currently experiencing
             clinical symptoms consistent with new-onset AMI, such as nitrate-unresponsive
             prolonged chest pain

          6. Patients with a history of bleeding diathesis or coagulopathy or patients in whom
             anti-platelet and/or anticoagulant therapy is contraindicated, patients who will
             refuse transfusion, or patients with an active peptic ulcer or history of upper
             gastrointestinal (GI) bleeding within the prior 3 months

          7. Patients with known mental or physical illness or known history of substance abuse
             that may cause non-compliance with the protocol, confound the data interpretation, or
             is associated with a life expectancy of less than one year

          8. Patients with severe allergy or known hypersensitivity or contraindication to aspirin,
             heparin/bivalirudin, clopidogrel, nitinol, stainless steel alloy, and/or contrast
             sensitivity that cannot be adequately pre-medicated

          9. Patients with a history of a stroke or transient ischemic attack (TIA) within the
             prior 6 months

         10. Patients with renal failure (estimated Glomerular Filtration Rate [eGFR] &lt;30 mL/min,
             calculated from serum creatinine by the Cockcroft-Gault formula)

         11. Patients with hepatic failure (Child-Pugh class C)

         12. Patients with hypercoagulable states that cannot be corrected by additional
             periprocedural heparin

         13. Patients presenting with cardiogenic shock at the time of the index procedure

         14. Patients with severe peripheral arterial, abdominal aortic, or thoracic aortic disease
             that precludes delivery sheath vascular access

         15. Patients in whom the aortic arch, innominate artery ostium, or proximal innominate
             artery is heavily calcified, severely atheromatous, or severely tortuous

         16. Patients with an innominate artery ostium diameter &lt;10 mm or &gt;25 mm

         17. Patients with a transverse aortic diameter &gt;43

         18. Patients with anatomic irregularities of the innominate artery that could prevent
             positioning of the TriGuard upper stabilizer and compromise stability of the device

         19. Patients with any other condition that would prevent adherence to the TriGuard HDH
             Instructions for Use

         20. Patients with contraindication to cerebral MRI

         21. Patients who have a planned treatment with any other investigational device or
             procedure during the study period

         22. Patients planned to undergo any other cardiac surgical or interventional procedure
             (e.g., concurrent coronary revascularization) during the TAVI procedure or within 10
             days prior to the TAVI procedure. NOTE: Diagnostic cardiac catheterization is
             permitted within 10 day prior to the TAVI procedure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra J Lansky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>alexandra.lansky@yale.edu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandra J Lansky, MD</last_name>
    <phone>(203) 737-2142</phone>
    <email>alexandra.lansky@yale.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raj Makkar, MD</last_name>
    </contact>
    <investigator>
      <last_name>Raj Makkar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale New Haven Hospital</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandra Lansky, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandra Lansky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington, D.C.</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ron Waksman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ron Waksman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Roven, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joshua Roven, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Delray Medical Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brij Mainj, MD</last_name>
    </contact>
    <investigator>
      <last_name>Brij Maini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brain Bethea, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivic Rajagopal, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vivic Rajogopal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Evanston</city>
        <state>Illinois</state>
        <zip>60208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Malaisrie, MD</last_name>
    </contact>
    <investigator>
      <last_name>Chris Malaisrie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>James Flaherty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Horwitz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Phillep Horwitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Institute of the South</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Fail, MD</last_name>
    </contact>
    <investigator>
      <last_name>Peter Fail, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Morristown Medical Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Kipperman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Kipperman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hasan Jilaihawi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hasan Jilaihawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamim Nazif, MD</last_name>
    </contact>
    <investigator>
      <last_name>Tamim Nazif, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>George Petrossian, MD</last_name>
    </contact>
    <investigator>
      <last_name>George Petrossian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samir Kapadia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Samir Kapadia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pinnacle Health</name>
      <address>
        <city>Harrisburg</city>
        <state>Pennsylvania</state>
        <zip>17101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mubashir Mumtaz, MD</last_name>
    </contact>
    <investigator>
      <last_name>Mubashir Mumtaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Methodist Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Neal Kleiman, MD</last_name>
    </contact>
    <investigator>
      <last_name>Neil Kleiman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abhijeet Dhoble, MD</last_name>
    </contact>
    <investigator>
      <last_name>Abhijeet Dhoble, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Research Center</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Brown, MD</last_name>
    </contact>
    <investigator>
      <last_name>David Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Scott Lim, MD</last_name>
    </contact>
    <investigator>
      <last_name>Scott Lim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Bersin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Robert Bersin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikos Werner, MD</last_name>
    </contact>
    <investigator>
      <last_name>Nikos Werner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitats-Herzzentrum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jochen Reinohl, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jochen Reinohl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamburg Univeristy Cardiovascular Center</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Schofer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Joachim Schofer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Leipzig Heart Institute</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Axel Linke, MD</last_name>
    </contact>
    <investigator>
      <last_name>Axel Linke, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Donato Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Federico De Marco, MD</last_name>
    </contact>
    <investigator>
      <last_name>Federico De Marco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Rafeele Hospital</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Azeem Latib, MD</last_name>
    </contact>
    <investigator>
      <last_name>Azeem Latib, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pieter Stella, MD</last_name>
    </contact>
    <investigator>
      <last_name>Pieter Stella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Israel</country>
    <country>United Kingdom</country>
  </removed_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 26, 2015</study_first_submitted>
  <study_first_submitted_qc>August 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2015</study_first_posted>
  <last_update_submitted>May 2, 2017</last_update_submitted>
  <last_update_submitted_qc>May 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cerebral protection, aortic stenosis, transcatheter aortic valve implantation, TAVI, TriGuard, Keystone Heart</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

